2 results found

Maria Francesca Testa, Mirko Pinotti, Alessio Branchini, Maria Elisa Mancuso, Francesco Bernardi, Dario Balestra

Background: Among F8 mutation types, main determinants of inhibitor development after replacement therapy in Hemophilia A, nonsense mutations display wide variation in the associated risk. Molecular m...

Molecular Medicine 2026-04-23 rs-9414495
F8 PTCs Hemophilia A translational readthrough inhibitory antibody peptide MHCII affinity personalized medicine

Margareth C. Ozelo, Bruna Webler, Julia Lima, Mariana Alves, Ana Karolina de Nunes, Ana Dantas, Rodrigo F. Alexandre, Daniela V. Pachito, Ieda Solange de Souza Pinto

Background: Despite therapeutic advances, important gaps persist in hemophilia care within public healthcare systems in middle-income countries. In Brazil, universal access to prophylaxis is ensured t...

Research Square 2026-04-21 rs-9471111
Hemophilia A Hemophilia B Needs Assessment Medication adherence Delphi Technique Brazil
Back to Top
Home
Browse
Submit
About
0.034870s